{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=63",
    "query": {
      "intervention": "Protein Control",
      "page": 63
    },
    "page_size": 10
  },
  "pagination": {
    "page": 63,
    "page_size": 10,
    "total_count": 3499,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=64&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=62&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T21:56:59.118Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01803594",
      "title": "Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Krill Oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lutein",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Nicotinic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Dairy phospholipids",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-08",
      "completion_date": "2015-03-13",
      "has_results": false,
      "last_update_posted_date": "2022-09-30",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 1,
      "location_summary": "Davis, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01803594"
    },
    {
      "nct_id": "NCT02316470",
      "title": "Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile"
      ],
      "interventions": [
        {
          "name": "VLA84",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2014-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 7,
      "location_summary": "Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02316470"
    },
    {
      "nct_id": "NCT00266656",
      "title": "Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Turner Syndrome"
      ],
      "interventions": [
        {
          "name": "Humatrope",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "20 Years",
        "sex": "FEMALE",
        "summary": "4 Years to 20 Years · Female only"
      },
      "enrollment_count": 69,
      "start_date": "2005-12",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-31",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Hartford, Connecticut + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00266656"
    },
    {
      "nct_id": "NCT05132686",
      "title": "The Healthy Diet and Lifestyle Study II",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Intra-Abdominal Fat"
      ],
      "interventions": [
        {
          "name": "IER+MED",
          "type": "BEHAVIORAL"
        },
        {
          "name": "MED/DER",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "35 Years to 69 Years"
      },
      "enrollment_count": 260,
      "start_date": "2022-01-20",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05132686"
    },
    {
      "nct_id": "NCT02501161",
      "title": "A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/liraglutide",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1012,
      "start_date": "2016-01-31",
      "completion_date": "2018-10-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 44,
      "location_summary": "Muscle Shoals, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 37 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02501161"
    },
    {
      "nct_id": "NCT02227862",
      "title": "Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Mylan's insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Lantus®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 558,
      "start_date": "2014-06",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 72,
      "location_summary": "Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more",
      "locations": [
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227862"
    },
    {
      "nct_id": "NCT04445025",
      "title": "Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Infertility",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Elagolix 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide Acetate 3.75 MG/ML",
          "type": "DRUG"
        },
        {
          "name": "Lab work",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Colorado Center for Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "42 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 42 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-09-01",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 1,
      "location_summary": "Lone Tree, Colorado",
      "locations": [
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445025"
    },
    {
      "nct_id": "NCT00253435",
      "title": "N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "131I-MIBG",
          "type": "RADIATION"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "1 Year to 29 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253435"
    },
    {
      "nct_id": "NCT00404417",
      "title": "Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin A / Placebo",
          "type": "DRUG"
        },
        {
          "name": "Botulinum Toxin A / Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo / Botulinum Toxin A",
          "type": "DRUG"
        },
        {
          "name": "Placebo / Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 160,
      "start_date": "2007-03",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00404417"
    },
    {
      "nct_id": "NCT07720726",
      "title": "Impact of Dysport on PMFF Donor Scar",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Cancer Excision Site",
        "Basal Cell Carcinoma",
        "Squamous Cell Carcinoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Abobotulinumtoxin-A",
          "type": "DRUG"
        },
        {
          "name": "Control- Saline injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-09-14",
      "completion_date": "2029-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-11-02T21:56:59.118Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07720726"
    }
  ]
}